Italy (IT)

close-button

Types of publications

Journal article
Book chapter / Article in edited volumes
Authored book
Translation
Thesis
Edited Volume
Conference contribution
Other publication type
Unpublished / Preprint

Publication year

From
To

Abstract

Journal

IFN-α in advanced well-differentiated neuroendocrine tumors: the neglected drug? (2018) Amoroso V, Pavel ME, Claps M, Roca E, Ravanelli M, Maroldi R, Oberg K, Berruti A Journal article Final analysis of time to subsequent disease progression/death in patients with metastatic enteropancreatic neuroendocrine tumours progressing under placebo and switched to lanreotide Autogel/depot 120mg in the CLARINET open-label extension (2018) Pavel ME, Cwikla J, Wolin E, Phan A, Raderer M, Sedlackova E, Cadiot G, et al. Conference contribution Final Progression-Free Survival Analyses for Lanreotide Autogel/Depot 120 mg in Metastatic Enteropancreatic Neuroendocrine Tumors: The CLARINET Extension Study (2018) Wolin EM, Pavel ME, Cwikla JB, Phan AT, Raderer M, Sedlackova E, Cadiot G, et al. Conference contribution ElevatION: NET-201 A Phase II Study to Evaluate the Efficacy and Safety of PDR001 in Patients with Metastatic, Well-Differentiated NET of Pancreatic/GI/Thoracic Origin or Poorly-Differentiated GEP NEC Who Have Progressed on Prior Treatment (2018) Yao JC, Fazio N, Li D, Pavel ME, Strosberg J, Bergsland E, Ruszniewski P, et al. Conference contribution Clinical efficacy of the Toll-like receptor 9 agonist cobitolimod using patient-reported-outcomes defined clinical endpoints in patients with ulcerative colitis (2018) Atreya R, Reinisch W, Peyrin-Biroulet L, Scaldaferri F, Admyre C, Knittel T, Kowalski J, et al. Journal article Sequential Therapies in Well-Differentiated Gastrointestinal Neuroendocrine Tumors G3 (NET G3): Platinum-Based vs. Platinum-Free Regimens (2018) Dal Buono A, Merola E, Delle Fave G, Wiedenmann B, Pavel ME Conference contribution Systemic Markers of Inflammation in Neuroendocrine Tumors (NETs) and Outcomes with Everolimus: A Pooled Analysis from the Randomized, Phase 3 RADIANT-3 and RADIANT-4 Trials (2018) Chan DL, Yao JC, Carnaghi C, Buzzoni R, Herbst F, Ridolfi A, Strosberg J, et al. Conference contribution What Characterizes Osteoarthritis: Ultrasound-Detected Inflammation but Not Osteophytes Is More Common in Hand Osteoarthritis Than in Painless Bony Enlargements (2018) Gasperi N, Adinolfi A, Kleyer A, Hagen M, Gasperi C, Weger M, Kiechl S, et al. Conference contribution RITUXIMAB IN SYSTEMIC SCLEROSIS : SAFETY AND EFFICACY DATA FROM THE EUSTAR NETWORK (2018) Elhai M, Distler O, Smith V, Matucci-Cerinic M, Alegre-Sancho JJ, Truchetet ME, Braun-Moscovici Y, et al. Conference contribution NEW SYSTEMIC SCLEROSIS RISK LOCI IDENTIFIED THROUGH A META-GWAS STRATEGY (2018) Lopez-Isac E, Acosta-Herrera M, Assassi S, Simeon CP, Carreira PE, Castellvi I, Ortego-Centeno N, et al. Conference contribution